USPTO Issues New Patents for Cell Source's Veto Cell Technology
Retrieved on:
Friday, March 19, 2021
NEW YORK, March 19, 2021 /PRNewswire/ --Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g.
Key Points:
- NEW YORK, March 19, 2021 /PRNewswire/ --Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g.
- Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology.
- Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist.
- "These issued patents reiterate the versatility of Veto Cells as a powerful, multi-faceted immunotherapy platform technology," said Dennis Brown, Chairman of Cell Source.